Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Inspyr Therapeutics Inc (NSPX)

Inspyr Therapeutics Inc (NSPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Inspyr Therapeutics Reports Financial Results and Business Update For Full Year 2020 AccessWire - Thu Apr 1, 2021

- Implements new corporate strategy to focus on precision therapeutics for the treatment of cancer - Strengthens pipeline by acquiring a proprietary portfolio of novel adenosine immuno-modulator compounds...

NSPX : 0.0027 (-18.18%)
Inspyr Therapeutics Further Strengthens Global Intellectual Property AccessWire - Thu Feb 18, 2021

WESTLAKE VILLAGE, CA / ACCESSWIRE / February 18, 2021 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics...

NSPX : 0.0027 (-18.18%)
Inspyr Therapeutics Secures $500,000 to Support the Development of its Adenosine Pipeline AccessWire - Tue Jan 12, 2021

- Proceeds support the development of lead asset, RT-AR001, an adenosine receptor antagonist - Funds were secured from an existing institutional investor WESTLAKE VILLAGE, CA / ACCESSWIRE / January 12,...

NSPX : 0.0027 (-18.18%)
Inspyr Therapeutics Strengthens Global Intellectual Property AccessWire - Thu Dec 10, 2020

- Expansion of patent portfolio of novel adenosine immuno-modulator compounds WESTLAKE VILLAGE, CA / ACCESSWIRE / December 10, 2020 / Inspyr Therapeutics, Inc. (OTC PINK:NSPX), a pharmaceutical company...

NSPX : 0.0027 (-18.18%)
Inspyr Therapeutics Reports 2020 Third Quarter Results and Business Update AccessWire - Tue Nov 24, 2020

- Implements New Corporate Strategy to Focus on Precision Therapeutics for the Treatment of Cancer - Strengthens Pipeline by Acquiring a Proprietary Portfolio of Novel Adenosine Immuno-Modulator Compounds...

NSPX : 0.0027 (-18.18%)
Inspyr Therapeutics Acquires a Novel Immuno-Onoclogy Precision Targeting Platform for the Treatment of Cancer AccessWire - Thu Oct 8, 2020

Preclinical data demonstrated delayed tumor growth, reduces metastases and anti-tumor immune response WESTLAKE VILLAGE, CA / ACCESSWIRE / October 9, 2020 / Inspyr Therapeutics, Inc. (OTC/PINK:NSPX), announces...

NSPX : 0.0027 (-18.18%)

Barchart Exclusives

2 Uranium Stocks With 50% or More Upside Potential Barchart - 1 hour ago
As U.S. passes the bill to ban uranium import from Russia, U.S. based uranium companies are sure to enjoy the increased demand. Here are 2 stocks with upside according to analysts. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot